• Explore /
  • Poster
  • / A phase II study of MOR208 plus idelalisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (MIRACLE).

A phase II study of MOR208 plus idelalisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (MIRACLE).

Abstract Poster

Authors

null

Clemens-Martin Wendtner

Klinikum Schwabing, Department I of Medicine, Academic Teaching Hospital of University of Munich, Munich, Germany

Clemens-Martin Wendtner , John C. Byrd , Barbara Eichhorst , Robin Foà , Michael Hallek , Peter Hillmen , Ulrich Jäger , Wojciech Jurczak , Peter Kelemen , Kamel Laribi , Talha Munir , Philipp B Staber , Stephan Stilgenbauer , Jennifer Ann Woyach

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Clinical Trial Registration Number

NCT02639910

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS7572)

DOI

10.1200/JCO.2016.34.15_suppl.TPS7572

Abstract #

TPS7572

Poster Bd #

128a

Abstract Disclosures

Similar Posters

First Author: John C. Byrd

First Author: Andrew David Zelenetz

First Author: Johannes Düll

First Author: Paul M. Barr